Jakob Weiss, MD, was the lead author on a study that used AI to determine a patient's cardiovascular risks based on a standard chest X-ray.

The randomized trial, expected to enroll at least 550 patients, will follow patients for a total of five years.

Simulation-based training can help cardiology fellows improve their TTE abilities, even when instructors or equipment are in short supply. 

Peter Libby, MD, a cardiovascular medicine specialist at Brigham and Women’s Hospital, explains his research into COVID-19 and how it damages the endothelium of blood vessels. 

What's next for TAVR? What trends should clinicians be focused on as time goes on? Kapadia shared his perspective in a new interview. 

A comparative meta-analysis found similar procedural outcomes, but higher 90-day mortality—partially attributable to a higher rate of comorbidities.

The new study, published in PLOS ONE, included registry data from nearly 4,500 patients. While COVID-19 patients faced a heightened risk of adverse cardiovascular outcomes early on, many of those risks faded after approximately one month. 

AVS, a Michigan-based medical device company, has said the funding will help accelerate research on its new Pulse P-IVL system. One clinical trial is already underway. 

Shimadzu Medical Systems USA released the latest version of its Trinias angiography system at the Radiological Society of North America (RSNA) 2022 meeting to address radiation concerns and to help improve workflow.
 

Christine Seidman, MD, director of the cardiovascular genetics program at Brigham & Women’s Hospital, spoke to us about using genetics to crack the code of cardiovascular disease.